195 related articles for article (PubMed ID: 38066899)
1. How to avoid early mortality in acute promyelocytic leukemia.
Odetola O; Tallman MS
Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):248-253. PubMed ID: 38066899
[TBL] [Abstract][Full Text] [Related]
2. Intravenous arsenic trioxide and all-trans retinoic acid as front-line therapy for low-risk acute promyelocytic leukemia.
Breccia M; Foà R
Expert Rev Hematol; 2019 Feb; 12(2):81-87. PubMed ID: 30572725
[TBL] [Abstract][Full Text] [Related]
3. [Acute Promyelocytic Leukemia: New treatment strategies with ATRA and ATO - AML-BFM-Recommendations].
Creutzig U; Dworzak M; von Neuhoff N; Rasche M; Reinhardt D
Klin Padiatr; 2018 Oct; 230(6):299-304. PubMed ID: 30399642
[TBL] [Abstract][Full Text] [Related]
4. [All-trans retinoic acid/arsenic trioxide combination therapy for a patient with acute promyelocytic leukemia on dialysis].
Nagao R; Hosoba R; Yahagi Y; Gunji T; Uryu H; Hattori D; Momoki M; Yamazaki H
Rinsho Ketsueki; 2019; 60(10):1431-1435. PubMed ID: 31695003
[TBL] [Abstract][Full Text] [Related]
5. [State-of-the-art treatment of acute promyelocytic leukemia].
Kiguchi T
Rinsho Ketsueki; 2018; 59(10):2007-2018. PubMed ID: 30305503
[TBL] [Abstract][Full Text] [Related]
6. Arsenic trioxide and all-trans retinoic acid (ATRA) treatment for acute promyelocytic leukemia in all risk groups: study protocol for a randomized controlled trial.
Zhang X; Zhang H; Chen L; Wang M; Xi J; Liu X; Xie M; Li D; Gulati ES; Gong S; Wang H
Trials; 2018 Sep; 19(1):476. PubMed ID: 30185214
[TBL] [Abstract][Full Text] [Related]
7. Treatment of Pediatric Acute Promyelocytic Leukemia with Retinoic Acid and Arsenic Trioxide along with Chemotherapy.
Srinivasan S; Dhamne C; Moulik NR; Chichra A; Tembhare P; Patkar N; Subramanian PG; Shetty D; Narula G; Banavali S
Indian J Pediatr; 2024 Jun; 91(6):564-570. PubMed ID: 37380920
[TBL] [Abstract][Full Text] [Related]
8. [Therapies for newly diagnosed acute promyelocytic leukemia].
Yokoyama Y
Rinsho Ketsueki; 2020; 61(9):1166-1173. PubMed ID: 33162512
[TBL] [Abstract][Full Text] [Related]
9. The characteristics and long-term outcomes of acute promyelocytic leukemia patients with early intracranial hemorrhage.
Li H; Niu T; Huang J; Xie L; He C; Li J; Xiang B; Cui X; Wu Y; Tang Y; Jia Y; Liu Z; Ma H
Int J Hematol; 2023 Apr; 117(4):538-543. PubMed ID: 36522588
[TBL] [Abstract][Full Text] [Related]
10. Acute promyelocytic leukemia current treatment algorithms.
Yilmaz M; Kantarjian H; Ravandi F
Blood Cancer J; 2021 Jun; 11(6):123. PubMed ID: 34193815
[TBL] [Abstract][Full Text] [Related]
11. [Arsenic trioxide in combination with all-trans retinoic acid for acute promyelocytic leukemia: a systematic review and meta-analysis].
Xu SN; Chen JP; Liu JP; Xia Y
Zhong Xi Yi Jie He Xue Bao; 2009 Nov; 7(11):1024-34. PubMed ID: 19912733
[TBL] [Abstract][Full Text] [Related]
12. The global problem of early deaths in acute promyelocytic leukemia: A strategy to decrease induction mortality in the most curable leukemia.
Jillella AP; Kota VK
Blood Rev; 2018 Mar; 32(2):89-95. PubMed ID: 29033137
[TBL] [Abstract][Full Text] [Related]
13. Acute promyelocytic leukemia (APL): remaining challenges towards a cure for all.
Stahl M; Tallman MS
Leuk Lymphoma; 2019 Dec; 60(13):3107-3115. PubMed ID: 31842650
[TBL] [Abstract][Full Text] [Related]
14. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia.
Lo-Coco F; Avvisati G; Vignetti M; Thiede C; Orlando SM; Iacobelli S; Ferrara F; Fazi P; Cicconi L; Di Bona E; Specchia G; Sica S; Divona M; Levis A; Fiedler W; Cerqui E; Breccia M; Fioritoni G; Salih HR; Cazzola M; Melillo L; Carella AM; Brandts CH; Morra E; von Lilienfeld-Toal M; Hertenstein B; Wattad M; Lübbert M; Hänel M; Schmitz N; Link H; Kropp MG; Rambaldi A; La Nasa G; Luppi M; Ciceri F; Finizio O; Venditti A; Fabbiano F; Döhner K; Sauer M; Ganser A; Amadori S; Mandelli F; Döhner H; Ehninger G; Schlenk RF; Platzbecker U; ; ;
N Engl J Med; 2013 Jul; 369(2):111-21. PubMed ID: 23841729
[TBL] [Abstract][Full Text] [Related]
15. Acute promyelocytic leukemia with myelofibrosis: A case report and literature review.
Xiao M; Qin L; Niu X; Zhou P; Niu J; Wei S; Li D; Dou L; Zhang W; Zhang L; Sun K; Bai Y
Medicine (Baltimore); 2021 Apr; 100(13):e24567. PubMed ID: 33787572
[TBL] [Abstract][Full Text] [Related]
16. PML-RARA transcript levels at the end of induction therapy are associated with prognosis in non-high-risk acute promyelocytic leukaemia with all-trans retinoic acid plus arsenic in front-line therapy: long-term follow-up of a single-centre cohort study.
Tang FF; Lu SY; Zhao XS; Qin YZ; Liu XH; Jia JS; Wang J; Gong LZ; Jiang Q; Zhao T; Shi HX; Chang YJ; Huang XJ; Jiang H
Br J Haematol; 2021 Dec; 195(5):722-730. PubMed ID: 34405393
[TBL] [Abstract][Full Text] [Related]
17. Assessment of Arsenic Trioxide and All-trans Retinoic Acid for the Treatment of Pediatric Acute Promyelocytic Leukemia: A Report From the Children's Oncology Group AAML1331 Trial.
Kutny MA; Alonzo TA; Abla O; Rajpurkar M; Gerbing RB; Wang YC; Hirsch BA; Raimondi S; Kahwash S; Hardy KK; Hardy S; Meshinchi S; Gamis AS; Kolb EA; Feusner JH; Gregory J
JAMA Oncol; 2022 Jan; 8(1):79-87. PubMed ID: 34762093
[TBL] [Abstract][Full Text] [Related]
18. Role of arsenic trioxide in acute promyelocytic leukemia.
Iland HJ; Seymour JF
Curr Treat Options Oncol; 2013 Jun; 14(2):170-84. PubMed ID: 23322117
[TBL] [Abstract][Full Text] [Related]
19. [Acute promyelocytic leukemia: state-of-the-art management].
Asou N
Rinsho Ketsueki; 2018; 59(6):725-734. PubMed ID: 29973452
[TBL] [Abstract][Full Text] [Related]
20. The design of selective and non-selective combination therapy for acute promyelocytic leukemia.
Jing Y; Waxman S
Curr Top Microbiol Immunol; 2007; 313():245-69. PubMed ID: 17217047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
